Replies to post #1511 on Synaptogenix Inc (SNPX)

[SF Wolf]

GentleGiant, thank you for your informative posts and the benefit of your obvious technical background in medical research.

Assuming that NTRP announces a positive outcome in their Ph2b study (and I am assuming they will based on animal studies, compassionate use cases, and the recent positive public statements by company officers) what, in your opinion, will be the most expeditious route for securing FDA approval for the use of Byrostating 1 in treating AD?